Abstract
Human monoclonal antibodies have been produced in a number of laboratories to a number of cell surface and cytoplasmic antigens. Although currently more difficult to produce than murine monoclonal antibodies, human monoclonal antibodies provide several potential advantages over conventional murine monoclonal antibodies in the therapy of human cancer. We review the human monoclonal antibodies produced to human tumors and describe our clinical experience with the use of human monoclonal antibodies in the treatment of recurrent cutaneous melanoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
